Stephen Phelan, MD
Endocrinology, Diabetes & Metabolism · Pawcatuck, CTNPI 1326142332
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,430 of the $8,113 with a category attached, or 91.6%. Johnson & Johnson accounts for 95.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $7,853 and has fallen 98.0% since, to $160 in 2025.
Across 14 payments — averaging $579.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$8K
- Abbott$100
- Amgen$77
- Radius Health, Inc.$51
- Novo Nordisk$50
- Mannkind Corporation$43
- plus $17 from 1 others
What the payments were for
- Speaking & faculty fees$7,43092%
- Travel & lodging$731%
- Food & beverage$4626%
- Education$1482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $7,776 |
| Abbott | 1 | $100 |
| Amgen | 1 | $77 |
| Radius Health, Inc. | 1 | $51 |
| Novo Nordisk | 1 | $50 |
| Mannkind Corporation | 1 | $43 |
| Corcept Therapeutics | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$7,430
How this compares
$8,113 in reported general payments places this provider in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 430 | $726,916 |
| JardianceEmpagliflozin | 296 | $400,594 |
| MounjaroTirzepatide | 181 | $307,544 |
| JanuviaSitagliptin Phosphate | 137 | $174,943 |
| Tresiba Flextouch U-200Insulin Degludec | 98 | $147,349 |
| Tresiba Flextouch U-100Insulin Degludec | 141 | $105,392 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 69 | $98,930 |
| FarxigaDapagliflozin Propanediol | 76 | $88,193 |
| TrulicityDulaglutide | 48 | $78,808 |
| Humalog Kwikpen U-100Insulin Lispro | 189 | $73,853 |
| ForteoTeriparatide | 13 | $72,585 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $71,392 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $70,919 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 44 | $60,046 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 59 | $51,611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $50 | $743,821454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Pawcatuck
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
- Glenn RichTrumbull$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.